Pharmaceutical and biotech firms are stepping forward to develop vaccines and treatments that target the infection caused by the Coronavirus (Covid-19).
Here are some of the companies CJsGO markets are keeping a close eye on:
Type: Vaccine
Stage: Preclinical
Name: BNT162
Background: On March 17, Pfizer announced that it would help develop and distribute BioNTech SE’s COVID-19 vaccine candidate, though the deal excludes China. BioNTech plans to put the vaccine candidate into clinical trials in late April, in Germany and the U.S. It is testing the vaccine in collaboration with Shanghai Fosun Pharmaceutical Group Co. Ltd. in China. Pfizer and BioNTech for several years have said they would partner to develop mRNA-based influenza vaccines.
YTD Performance: 104%
- Armand Roos: LSU Health Shreveport has been up to the challenge of COVID-19, vaccinationson January 16, 2021
In addition to being the only Pfizer & BioNTech vaccine trial site in North Louisiana, LSUHS technologies (S-ARCA and B-ARCA) were licensed by ...
- 'Frustrating and confusing': Beaufort hospital to cancel 6K vaccinations due to shortageon January 16, 2021
The cancellations are necessary because the hospital placed an order for 2,000 does of the Pfizer-BioNTech vaccine to be delivered early next week, ...
Type: Treatment
Stage: Preclinical
Background: Vir said Feb. 25 it is collaborating with Shanghai-based WuXi Biologics to test monoclonal antibodies as a treatment for COVID-19. If the treatment is approved, WuXi will commercialize it in China, while Vir will have marketing rights for the rest of the world. The preclinical company is run by George Scangos, the former CEO of Biogen. It later announced a partnership with Biogen to help develop and manufacture its monoclonal antibodies as a potential treatment for COVID-19. Biogen will handle clinical manufacturing of Vir’s antibodies, the company said.
YTD Performance: Vir 324.9%; Biogen’s 4.9%
- InvestorChannel's Covid-19 Watchlist Update for Friday, January, 15, 2021, 16:28 ESTon January 15, 2021
Vir Biotechnology Inc. (VIR) USD 39.31 (7.73%)n- BioCryst ... USD 8.80 (2.44%)n- Gilead Sciences Inc. (GILD) USD 63.33 (1.49%)n- Merck & Co., Inc.
- It's important for antibodies to 'control the virus as it evolves': Vir Biotechnology CEOon January 15, 2021
George Scangos, Vir Biotechnology President and CEO joins Yahoo ... American Robotics Inc. touted the advantage of its machines as being able to ...
Type: Treatment
Stage: Phase 3 clinical trials
Name: remdesivir
Background: Gilead is a longtime drugmaker best known for developing the first major cure for hepatitis-C in Sovaldi, a therapy that changed the standard of care for that disease but also kicked off the national debate about drug pricing. The company has experience developing and marketing HIV drugs, including Truvada for pre-exposure prophylaxis (PrEP), its preventive HIV medicine. Along with U.S. trials, Gilead is conducting a randomized, controlled clinical trial in Wuhan, testing remdesivir as a treatment for mild to moderate forms of pneumonia in people with the virus. The trial was given the go-ahead by China’s Food and Drug Administration in February.
YTD Performance: Shares of Gilead are up 13.4%.
- Caledonia River Valley's trick is no treat for Mt. Gileadon January 17, 2021
Caledonia River Valley took control early and methodically pulled away to beat Mt. Gilead 108-45 for an Ohio boys basketball victory on January 16.
- 'Gilead (GILD) Has No Near-Term Growth Drivers', Says Nelson Roberts Investment Advisorson January 17, 2021
Additionally, UnitedHealth Group said it would not cover Gilead's other HIV drug, Descovy. Lastly, the multiple acquisitions that Gilead has made recently ...
Type: Pandemic adjuvant platform for vaccines
Name: AS03 Adjuvant System
Background: GSK is another leading vaccine maker, having brought to market vaccines for human papillomavirus (HPV) and the seasonal flu, among others. On Feb. 3, it said the CEPI-funded University of Queensland will have access to the British drugmaker’s vaccine adjuvant platform technology, which is believed to both strengthen the response of a vaccine and limit the amount of vaccine needed per dose. On Feb. 24, GSK said that Clover Biopharmaceuticals Inc., a Chinese biotechnology company, is also using its adjuvant technology in combination with its vaccine candidate, COVID-19 S-Trimer, in preclinical studies. Dr. Thomas Breuer, chief medical officer for GSK Vaccines, is leading work on vaccines and the adjuvant platform.
YTD Performance: 23.5%.
- Gastrointestinal OTC Drugs Market: Know about Impact of Covid-19 by Top Companies like ...on January 16, 2021
GlaxoSmithKline; Pfizer; Johnson & Johnson; Bayer; Procter & Gamble; Perrigo; Abbott; Sanofi; Teva Pharmaceutical; Nestle; Boehringer Ingelheim ...
- Hives Treatment Market 2021-2027 study and future prospects including key players: Novartis, F ...on January 16, 2021
Hives Treatment Market 2021-2027 study and future prospects including key players: Novartis, F. Hoffmann-La Roche, Elorac, GlaxoSmithKline PLC.
Type: Vaccine
Stage: Preclinical
Background: Heat Biologics has previously announced that it is developing a vaccine for the novel coronavirus with the University of Miami Miller School of Medicine. It disclosed March 17 in a financial filing that its COVID-19 vaccine candidate had been added to the World Health Organization’s “draft landscape” of 41 candidate vaccines. The company also recently joined the Alliance for Biosecurity, which may help it “secure government funding to support its rapid development, production, and distribution” of its COVID-19 vaccine, according to Maxim Group analysts.
YTD Performance: 19%.
- Coronavirus (COVID 19) Vaccine Pipeline Assessment 2020on January 16, 2021
Heat Biologics Inc./University of Miami ... Sanofi Pasteur/Translate Bio Inc. • Vaxart Inc. ... CanSino Biological Inc/Beijing Institute of Biotechnology
Type: DNA-based vaccine
Stage: Human Trials
Name: INO-4800
Background: Another CEPI grantee, awarded $9 million, Inovio has said it already began preclinical testing and small-scale manufacturing.
YTD Performance: 124.6%.
- Global Transmucosal Drug Delivery Market (2021) to Witness Huge Growth by 2026 | 3M ...on January 16, 2021
Inovio Pharmaceuticals Inc. Lohmann Therapy-Systems Corp (LTS Lohmann Therapie Systeme AG); MedPharm LTD; Mylan Inc. Nemaura Pharma Ltd ...
- Global Pol Polyprotein Market is to Witness Significant Growth between 2020-2026 with leading ...on January 16, 2021
Inovio Pharmaceuticals Inc. Johnson & Johnson. You can get free sample report includes TOC, Tables, and Figures of Pol Polyprotein market 2015- ...
Type: Vaccine
Name: TBD
Background: On Feb. 11, J&J said it is working with BARDA to test its vaccine candidate, with both organizations providing funding for research and development and the public-health organization funding the Phase 1 trials. Similar to GSK, J&J’s AdVac and PER. C6 technologies are used to improve the development process for a vaccine and were also used to develop J&J’s experimental Ebola vaccine. “We are also in discussions with other partners, that if we have a vaccine candidate with potential, we aim to make it accessible to China and other parts of the world,” Dr. Paul Stoffels, J&J’s chief scientific officer, said in a statement. On March 13, J&J said it started preclinical testing on multiple candidates in collaboration with Beth Israel Deaconess Medical Center in Boston, and it aims to have a vaccine candidate by the end of the month. J&J also said in February that it partnered with BARDA on a project that aims to screen existing antiviral medications, including experimental or approved therapies, that may be effective against COVID-19.
YTD Performance: Down -7.5%.
- Virginia health officials say COVID-19 vaccine limited until March or Aprilon January 17, 2021
By then, Avula said, increased production and introduction of new vaccines by AstraZeneca and Johnson & Johnson could become available.
- [Herald Interview] Oral health care in the hands of consumerson January 17, 2021
“What COVID-19 has done is accelerate trends that have already been in place. We increasingly see the value of connectivity. Because the more people ...
Type: RNA-based vaccine
Stage: Human Trials
Name: mRNA-1273
Background: Moderna received funding from CEPI in January to develop an mRNA vaccine against COVID-19. On Feb. 24, it said it had shipped the first batch of mRNA-1273 to the NIAID for a Phase 1 clinical trial in the U.S.
YTD Performance: 51.4%.
- List of mrna vaccineson January 16, 2021
--(BUSINESS WIRE)-- Moderna, Inc. When this mRNA is injected into muscle, a person's own body will begin to make the key viral spike protein.
- CMLViz Newson January 16, 2021
Moderna Inc. NASDAQ:MRNA. 129.66. -0.06 (-0.05%). 4:41:58 PM EDT: $129.89 +0.23 (+0.18%). StockTwits Share Twitter Share Facebook Share ...
Type: Treatment
Stage: Available
Name: Hydroxychloroquine (HCQ), sold under the brand name Plaquenil
Background: Hydroxychloroquine (HCQ) is a medication used to prevent and treat malaria in areas where malaria remains sensitive to chloroquine.
Mylan NV said Thursday it was restarting production of a medication to treat malaria — hydroxychloroquine sulfate tablets — that could potentially treat COVID-19 if it’s approved by the federal government.
The World Health Organization has listed it as a drug under investigation for treatment against the novel coronavirus, although it isn’t approved for that use in the United States. It is also used to treat rheumatoid arthritis and lupus erythematosus. Mylan said that it restarted production at its Morgantown, West Virginia, plant of the medication and has enough active pharmaceutical ingredient to start supply in mid-April and provide at some point after the ramp-up to 50 million tablets that could treat 1.5 million COVID-19 patients.
YTD Performance: Down −25.75%
- Why are Some California Doctors Refusing to Prescribe Certain Meds to COVID Patientson January 16, 2021
“When I asked one doc about getting Hydroxychloroquine he acted like I ... America's Frontline Doctors report the restriction on HCQ is severe in ...
- Hydroxychloroquine in the post-COVID-19 era: will this pandemic upset decades of clinical practice?on January 16, 2021
... for the treatment of pneumonia: hydroxychloroquine (HCQ) was recommended for COVID-19 hospitalized patients with moderate to severe disease.
Type: vaccines
Phase: preclinical
Background: Novavax, a preclinical biotechnology company, announced Feb. 26 it had several vaccine candidates in preclinical animal studies, and that it plans to initiate a Phase I clinical study by June. In March the company it had received $4 million from CEPI to develop a COVID-19 vaccine and that Emergent BioSolutions Inc. EBS, 10.966% would support contract development and manufacturing for the experimental vaccine.
YTD Performance: 165.6%.
- 4 more Covid vaccines in different stages of trial: Serum Institute of Indiaon January 17, 2021
Under an agreement with the US drug developer, the Pune based drugmaker will develop two hundred crore doses of Novavax's vaccine candidate ...
- Impact of COVID-19 on Human Vaccine Adjuvants Market by 2026 | SEPPIC, Brenntag Biosector ...on January 17, 2021
SEPPIC, Brenntag Biosector, Novavax, SPI Pharma, Avanti Polar Lipids, CSL Limited, GSK, Aphios. The key questions answered in this report:.
Type: Treatment
Stage: Preclinical
Name: No name yet
Background: On Feb. 4, Regeneron announced it is working on developing monoclonal antibodies as treatments for COVID-19. The company’s VelocImmune platform uses genetically-engineered mice with humanized immune systems in preclinical testing. “We are aiming to have hundreds of thousands of prophylactic doses ready for human testing by end of August,” a spokesperson said. Christos Kyratsous, VP of infectious disease R&D and viral vector technology, is running the project.
YTD Performance: 29.8%.
- Armand Roos: LSU Health Shreveport has been up to the challenge of COVID-19, vaccinationson January 16, 2021
In addition to being the only Pfizer & BioNTech vaccine trial site in North Louisiana, LSUHS technologies (S-ARCA and B-ARCA) were licensed by ...
- 'Frustrating and confusing': Beaufort hospital to cancel 6K vaccinations due to shortageon January 16, 2021
The cancellations are necessary because the hospital placed an order for 2,000 does of the Pfizer-BioNTech vaccine to be delivered early next week, ...
Type: Vaccine
Stage: Preclinical
Name: No name yet
Background: Starting Feb. 18, Sanofi is working with BARDA to test a preclinical vaccine candidate for severe acute respiratory syndrome (SARS) for COVID-19 using its recombinant DNA platform. It has a long history of producing vaccines in its Sanofi Pasteur business and acquired this candidate through its 2017 acquisition of Protein Sciences for $750 million. The French drugmaker previously worked with the organization on flu vaccines. Scientists in Meriden, Ct., are working on the vaccine; David Loew, Sanofi Pasteur’s EVP, is leading the project.
YTD Performance: 14.4%.
- Benign Prostatic Hyperplasia (BPH) Drugs Market to eyewitness massive growth by 2025 ...on January 17, 2021
GlaxoSmithKline, Astellas Pharma, Sanofi, Eli Lilly – Murphy's Hockey Law ...
- Comprehensive Report on Surgical Anti-Adhesion Products Market 2021 | Size, Growth, Demand ...on January 17, 2021
Ethicon, SANOFI, Baxter International, Pathfinder Cell Therapy, Covidien, Integra Life Sciences, FzioMed, Anika Therapeutics, Bioscompass, ...
Type: Treatment
Stage: Preclinical
Name: TAK-888
Background: The Japanese drugmaker said March 4 it plans to test hyperimmune globulins for people who are at high risk for infection. As part of its research, which will be performed in Georgia, Takeda said it would need access to plasma from people who have recovered from COVID-19 or those who have received a vaccine if one is developed. Dr. Rajeev Venkayya, president of Takeda’s vaccine business, is the co-lead of the company’s COVID-19 response team. Like J&J, Takeda plans to examine whether other therapies, both experimental or with regulatory approval, may have treatment potential.
YTD Performance: 29.0%.
- Global Over the Counter (OTC) Drugs Market Growth Analysis, Forecasts to 2027 : Johnson ...on January 16, 2021
Takeda Pharmaceutical Company Limited; Sanofi; F. Hoffmann-La Roche Ltd; Bayer AG. Market Analysis and Insights: Global Over the Counter (OTC) ...
- Myelodysplastic Syndromes (MDS) Market 2021 Industry Trend, Size Estimation, Industry Outlook ...on January 16, 2021
Takeda Pharmaceutical Company Limited; Onconova Therapeutics; Helsinn Healthcare SA; Boehringer Ingelheim International GmbH; Johnson & ...
Type: Vaccine
Stage: Preclinical
Background:Vaxart was one of the first companies to announce plans to develop a vaccine when it did so Jan. 31. In March the clinical-stage company announced that Emergent BioSolutions will help develop and manufacture its oral vaccine candidate. “We believe an oral vaccine administered using a room temperature-stable tablet may offer enormous logistical advantages in the roll-out of a large vaccination campaign,” Vaxart CEO Wouter Latour said in a March 18 news release. The company plans to start a Phase 1 clinical trial in the U.S. in the second half of 2020, a company executive said.
YTD Performance: 516.3%.
- Impact Analysis of Covid-19 On Vaccines Delivery Market Expected to Showcase Extensive Growth ...on January 16, 2021
... Market Expected to Showcase Extensive Growth at a Highest CAGR with- Becton Dickinson and Company (BD), BioCSL, Novavax Inc., Vaxart Inc.
- Smoking Cessation Market Report- Opportunities, Growth, Insights, Emerging Trends | Pfizer Inc ...on January 16, 2021
Vaxart Inc. Sanofi. Altria Group Inc. Rock Creek Pharmaceuticals Inc. Achieve Life Science Inc. ICON Plc. Smoking Cessation Market Report provides ...
Bitcoin
Ethereum
Xrp
Bitcoin cash
Eos
Tezos
Dash
Stellar
Ethereum classic
Zcash
Thank you for your Bitcoin donation
Scan the QR code or copy the address below into your wallet to send Bitcoin
Thank you for your Ethereum donation
Scan the QR code or copy the address below into your wallet to send Ethereum
Thank you for your Xrp donation
Scan the QR code or copy the address below into your wallet to send Xrp
Thank you for your Bitcoin cash donation
Scan the QR code or copy the address below into your wallet to send Bitcoin cash
Thank you for your Eos donation
Scan the QR code or copy the address below into your wallet to send Eos
Thank you for your Tezos donation
Scan the QR code or copy the address below into your wallet to send Tezos
Thank you for your Dash donation
Scan the QR code or copy the address below into your wallet to send Dash
Thank you for your Stellar donation
Scan the QR code or copy the address below into your wallet to send Stellar
Thank you for your Ethereum classic donation
Scan the QR code or copy the address below into your wallet to send Ethereum classic
Thank you for your Zcash donation
Scan the QR code or copy the address below into your wallet to send Zcash